Filing summary
Issuer mismatch: The request identifies TALPHERA, INC., but the supplied Form 10-K is for ACELRX PHARMACEUTICALS, INC. Verify that this is the intended filing before relying on the figures below.
Business context and reporting period
This is AcelRx Pharmaceuticals’ annual report for the fiscal year ended December 31, 2018, filed March 7, 2019. The company develops and commercializes sublingual sufentanil products for acute pain in medically supervised settings. FDA approved DSUVIA in November 2018; its U.S. commercial launch began in Q1 2019. DZUVEO received European Commission approval in June 2018. Zalviso is marketed in Europe by Grünenthal, while the timing of a U.S. NDA resubmission remained under evaluation.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $2.2 million | $8.0 million |
| Operating expenses | $37.9 million | $46.7 million |
| Operating loss | $35.7 million | $38.7 million |
| Net loss | $47.1 million | $51.5 million |
| Net loss per share | $0.81 | $1.10 |
| Cash, cash equivalents and short-term investments at year-end | $105.7 million | $60.5 million |
| Working capital at year-end | $92.1 million | $49.8 million |
| Debt at year-end | $12.0 million | $19.1 million |
- 2018 revenue comprised $1.3 million under the Grünenthal agreements and $0.8 million under the Department of Defense contract. The DoD contract period ended February 28, 2019.
- Operating cash use was $29.1 million, versus $29.8 million in 2017. Investing activities used $10.9 million; financing activities provided $75.0 million.
- Cash increased primarily due to equity financings. Two 2018 public offerings generated $64.8 million in net proceeds, and the Cantor sales agreement generated another $16.8 million net. Shares outstanding rose from 50.9 million to 78.8 million during 2018.
- In addition to Hercules debt, the balance sheet included a $93.7 million liability related to the sale of future Zalviso royalties to PDL. That transaction directs a substantial portion of European Zalviso royalties and specified milestones to PDL, up to its contractual cap.
- The company reported an accumulated deficit of $345.0 million and stockholders’ equity of $4.3 million. It has incurred recurring losses and negative operating cash flows since inception.
Changes versus prior periods
- Annual revenue fell 73% from 2017, principally because Grünenthal worked down existing Zalviso inventory and DoD contract revenue declined sharply from 2016 levels.
- Annual net loss narrowed by $4.4 million, as lower operating expenses and interest expense more than offset reduced revenue. R&D fell 32% to $13.1 million, mainly reflecting completion of late-stage development work; general and administrative expense rose 25% to $20.8 million as the company prepared for DSUVIA commercialization.
- Fourth-quarter 2018 revenue was $0.6 million, compared with $0.7 million in Q4 2017. Q4 operating expenses rose to $11.6 million from $8.5 million, and net loss widened to $12.6 million from $9.9 million.
- Debt declined after $7.7 million of repayments, while equity financings materially increased cash and the share count.
Outlook, commentary and material risks
- Management expected available capital to fund planned operations through at least the end of Q1 2020, but said existing resources likely would not fund the company through self-sustaining revenue. It expected continued significant losses in 2019.
- Management planned to build U.S. DSUVIA commercial capacity and install an automated packaging line, with qualified product expected from the line beginning in 2020 and lower cost of goods sold anticipated thereafter. 2019 general and administrative expenses were expected to increase to support the launch.
- DSUVIA distribution is restricted by a REMS to certified, medically supervised facilities; it is not available through retail pharmacies or for outpatient use. Adoption, facility certification, formularies, reimbursement, pricing and safe REMS compliance are key commercial uncertainties.
- Zalviso had a prior FDA Complete Response Letter. Although the company reported favorable IAP312 device-error results, FDA review of device errors and inadvertently misplaced tablets could require further work, restrict the label, or delay or prevent approval. Resubmission timing was not specified.
- The company had not secured a European commercialization partner for DZUVEO. Its Zalviso European revenue share is reduced by the PDL monetization, and it anticipated minimal European Zalviso royalty revenue in 2019.
- Supply is concentrated: the company relies on a single qualified sufentanil API supplier and single-source manufacturers for important product and device components, with no redundant supply agreements in place. Manufacturing scale-up and packaging automation also present execution risks.
- Hercules debt was scheduled to mature in March 2020 and was secured by substantially all assets other than intellectual property. Future financing could dilute shareholders or impose restrictions. The company also faces opioid-related regulatory, safety, reputational and potential litigation risks; it reported no material legal proceedings at the filing date.
- Auditors gave an unqualified opinion on the financial statements and internal controls. Management also concluded internal control over financial reporting was effective as of year-end.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for AcelRx, not Talphera.
- Review DSUVIA launch performance, certified-facility adoption, formulary access, net pricing and post-approval safety disclosures.
- Check current cash burn and financing needs against the stated runway through Q1 2020, including the March 2020 Hercules maturity.
- Track the timing and FDA requirements for Zalviso NDA resubmission, including any treatment of device errors and misplaced tablets.
- Assess DZUVEO partnership progress and the pace of Grünenthal’s Zalviso sales, including the effects of the PDL royalty arrangement.
- Monitor production capacity, automated packaging-line validation, single-source supply exposure and the economics of Zalviso supply under its transfer-price terms.